"Pill-in-Pocket" anticoagulation for stroke prevention in atrial fibrillation.
Graham PeighRod S PassmanPublished in: Journal of cardiovascular electrophysiology (2023)
Uninterrupted anticoagulation for atrial fibrillation (AF), regardless of AF burden, is deeply rooted in practice since the early anticoagulation trials. However, uninterrupted anticoagulation is not without risks, and may not be beneficial for allcomers with a history of AF. Indeed, contemporary data that support a critical duration threshold of AF that benefits from anticoagulation, and a temporal association between stroke and multihour AF episodes, compel the study of a more targeted approach to AF anticoagulation. In this review, we discuss data that support further investigation of "pill in the pocket" anticoagulation for AF, and introduce the pivotal Rhythm Evaluation for Anticoagulation Therapy for Atrial Fibrillation (REACT-AF) trial that will robustly evaluate this strategy.
Keyphrases
- atrial fibrillation
- catheter ablation
- direct oral anticoagulants
- oral anticoagulants
- left atrial
- left atrial appendage
- heart failure
- percutaneous coronary intervention
- clinical trial
- electronic health record
- healthcare
- venous thromboembolism
- randomized controlled trial
- risk factors
- risk assessment
- study protocol
- machine learning
- climate change
- coronary artery disease
- heart rate
- mitral valve
- deep learning